Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Intelligence

Set Alert for Market Intelligence

Value Added Medicines Hold Promise Despite Challenges

An IQVIA report dives into how technology can facilitate a digital future for value added medicines, while discussing the market size, opportunities, scope of growth and challenges for this emerging sector in healthcare.

Value-Added Medicines Market Intelligence

Podcast: Celltrion’s Subcutaneous Infliximab And The Future Of Biosimilars

In this podcast discussion, Generics Bulletin’s David Wallace talks to Informa Pharma Consulting’s Duncan Emerton about Celltrion’s CHMP nod for subcutaneous Remsima, the product’s imminent approval and launch, and what it means for the future of biosimilars.

Biosimilars Strategy

UK Concessions Fail To Match Falling Prices

UK concession prices have a history of often failing to keep up with rising prices in the marketplace. However, the latest figures from WaveData suggest that even when prices are falling, concessions can sometimes struggle to compensate independent pharmacists at an adequate price level.

United Kingdom Pricing Strategies

Indian Growth Expected To Top A Tenth

Indian credit rating agency ICRA has forecast that the country’s pharmaceutical industry will remain on a steady 11%-13% growth path this fiscal year, underpinned by healthy domestic demand, new launches and market share gains.

Market Intelligence India

Awareness Rate For Biosimilars Goes Up To 90%

An ASBM survey of 575 biologic prescribers in six western European countries has found that 90% of physicians are familiar with biosimilars, compared to 76% in 2013. The results were presented and discussed at the 2019 ESMO Congress.

Market Intelligence Biosimilars

‘Perverse’ Tactics Cost US $10bn In Biosimilar Savings

The AAM’s Biosimilars Council has said “rebate traps” and other barriers to biosimilar adoption have cost the US healthcare system $2.2bn in lost savings since 2015. That’s on top of patent abuses which the council calculated in a June report have cost the healthcare system $7.6bn – bringing total lost savings from biosimilars to nearly $10bn.

Market Intelligence Biosimilars
See All